6533b831fe1ef96bd1299b06

RESEARCH PRODUCT

The role of nesfatin and selected molecular factors in various types of endometrial cancer

Violetta FilasJanina MarkowskaMonika SzarszewskaMarian GrybośAnna GrybośAnna MarkowskaPaweł KnappAndrzej MarszałekMalgorzata SwornikKatarzyna Wójcik-krowiranda

subject

AdultC-MetARID1AAdipokineMLH1chemistry.chemical_compoundNESF-1Biomarkers TumormedicineHumansNucleobindinsc-METAgedRetrospective StudiesAged 80 and overbusiness.industryEndometrial cancerMLH1Obstetrics and GynecologyMiddle AgedPrognosismedicine.diseaseARID1AImmunohistochemistryMSH2Endometrial NeoplasmsDNA-Binding ProteinschemistryMSH2endometrial cancerCancer researchImmunohistochemistryFemaleMetabolic syndromebusinessTranscription Factors

description

Objectives: Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET and ARID1A are also related to prognosis in endometrial cancer. Material and methods: Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF1, MLH1, MSH2,c-MET and ARID1A were examined. Results: In this study on protein expression, EC tissues manifested (although insignificantly) an elevated expression of NESF-1 in type II EC. In type I EC, NESF-1 expression was significantly higher in G1 in comparison to G2 and G3 together. A significantly lower expression of MLH1 was demonstrated in type I EC. Conclusions: The most pronounced expression involved c-MET in all EC I and EC II tissues (in over 80% of cases). A tendency was detected for a high expression of NESF-1 in patients with type II EC, who also exhibited a high expression of MSH2.

yearjournalcountryeditionlanguage
2019-01-01Ginekologia Polska
https://doi.org/10.5603/gp.2019.0099